Alector Stock

Alector EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Alector (ALEC) as of Aug 9, 2026 is -1.40. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.41 — a change of -0.56% (higher).

EV/EBIT

-1.40

YoY

-0.56%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Alector is 2026 -1.40 . EV/EBIT (Enterprise Value to EBIT) of Alector was 2025 -1.41 . It decreases by -0.56% higher compared to the previous year.

The Alector EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.33 base
Jan 1, 2020
-1.99 base
Jan 1, 2021
-14.67 base
Jan 1, 2022
-1.80 base
Jan 1, 2023
-1.43 base
Jan 1, 2024
-0.64 base
Jan 1, 2025
-1.10 base
Jan 1, 2026 (e)
-36.83 base
YEARPRICE-TO-EBIT
2026 est -36.83
2025 -1.10
2024 -0.64
2023 -1.43
2022 -1.80
2021 -14.67
2020 -1.99
2019 -3.33
2018 -
2017 -
2016 -
Access this data via the Eulerpool API

Alector Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Alector's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Alector's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Alector's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Alector grows earnings faster than its peers.

Alector Stock analysis

What does Alector do? Alector Inc. is a biotechnology company that was founded in 2013. The company's core competency is developing targeted therapies for previously incurable neurodegenerative diseases. The company is based in South San Francisco, California, and was founded by a group of renowned scientists. The founders aimed to develop innovative approaches to treat Alzheimer's and other neurodegenerative diseases by drawing inspiration from the processes of the immune system. Alector has a unique business model based on identifying antibodies to combat neurodegeneration. The company works closely with academics, pharmaceutical partners, and clinicians to develop drug candidates targeting various aspects of these serious diseases. Alector has developed a platform technology called the "Lead-Selective Integrated Discovery Platform" (LSP) that sets it apart. This platform is capable of identifying specific antibodies that can help inhibit disease mechanisms in neurodegenerative diseases. Alector has several products in various stages of development. A promising drug, AL001, is currently in Phase 1b/2a of clinical development for the treatment of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The drug aims to prevent overactivation of the immune system in the brain, which can contribute to disease symptoms. The company is also working on another drug, AL002, targeting Alzheimer's disease. It is still in preclinical development. Alector has also entered into a partnership with AbbVie Inc. (NYSE: ABBV) to develop antibody-based therapies for Alzheimer's disease and other neurological disorders. In addition to developing drug candidates, Alector also collaborates with other companies to make its technology platform accessible to other industries. In 2019, the company signed an agreement with GlaxoSmithKline plc (NYSE: GSK) granting GlaxoSmithKline access to the LSP platform. In summary, Alector Inc. is a leading biotechnology company specializing in the development of antibody-based therapies for neurodegenerative diseases. With innovative technology platforms and partnerships with other companies, Alector aims to create new treatment options for incurable diseases such as Alzheimer's and ALS. Alector is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alector stock

EV/EBIT (Enterprise Value to EBIT) of Alector is -1.40 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Alector changed from -1.41 to -1.40, representing a -0.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Alector since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Alector with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Alector

All Key Metrics — Alector